Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of the disease. Our computational approach to polypharmacology is unique in the industry. We use a proteome-wide lens to evaluate multiple novel and rare on and off-target interactions simultaneously. We’re also the only company of our kind that integrates science to advance molecules downstream. A structure-based view keeps our work accountable to biology, chemistry, physics, and genomics. To learn more about Cyclica and how we partner, please visit www.cyclicarx.com